Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [1410]

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal...

Gynaecological cancers in the era of fertility preservation - A new special issue from ecancer

Gynaecological cancers in the era of fertility preservation - A new special issue from ecancer

FDA approves niraparib for first-line maintenance of advanced ovarian cancer

FDA approves niraparib for first-line maintenance of advanced ovarian cancer

AACR 2020: Study of nearly 10,000 women explores feasibility and safety of multi-cancer blood test

AACR 2020: Study of nearly 10,000 women explores feasibility and safety of multi-cancer blood test

AACR 2020: New therapy with potential benefit for underserved patients with lung and ovarian cancers

AACR 2020: New therapy with potential benefit for underserved patients with lung and ovarian cancers

New targeted agent produces considerable responses in patients with uterine cancer

New targeted agent produces considerable responses in patients with uterine cancer

Gene signature found for poor response to standard chemotherapy in rare uterine cancer

Gene signature found for poor response to standard chemotherapy in rare uterine cancer

Human uterus colonised by clones with cancer-driving mutations that arise early in life

Human uterus colonised by clones with cancer-driving mutations that arise early in life

Drug overcomes chemotherapy resistance in ovarian cancer

Drug overcomes chemotherapy resistance in ovarian cancer

Study finds evidence for existence of elusive 'metabolon'

Study finds evidence for existence of elusive 'metabolon'

More from ecancer